Literature DB >> 22469474

Subclinical infections with Crimean-Congo hemorrhagic fever virus, Turkey.

Hürrem Bodur1, Esragül Akinci, Sibel Ascioglu, Pinar Öngürü, Yavuz Uyar.   

Abstract

To investigate Crimean-Congo hemorrhagic fever virus in Turkey, we conducted a seroepidemiologic survey during January-April 2009. Seroprevalence of infection was 10% in a sample from an outbreak region and increased with patient age, indicating that the virus had been previously present in Turkey. We also estimated that 88% of infections were subclinical.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22469474      PMCID: PMC3309668          DOI: 10.3201/eid1804.111374

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Crimean-Congo hemorrhagic fever virus (CCHFV) infection was first recognized in Turkey in 2002. Since that time, the number of diagnosed cases has increased to the magnitude of an outbreak with major public health consequences (,). Although the clinical spectrum may change from asymptomatic infection to severe hemorrhagic disease, most studies to date have included only symptomatic cases (–). Therefore, the true incidence of infection with the virus, the full spectrum of severity of disease, and its epidemiologic features are unknown. The purpose of our study was to investigate the seroprevalence of CCHFV infection in a sufficiently large sample representative of the region affected during this outbreak in Turkey and to describe the main epidemiologic features, including the proportion of subclinical cases.

The Study

During January–April 2009, we conducted a survey that included obtaining venous blood samples from participants. The study sample was selected by using a random geographic cluster sampling stratified by age and sex from rural residential areas of Turkey where 99.5% of CCHF cases were reported (Figure 1). Only adults >18 years of age who were living in the study area for >1 year were eligible for the study. The study was approved by the Central Ethics Committee, and informed consent was obtained from all participants. A study questionnaire included questions on demographics, socioeconomic status, behavior characteristics, medical history, known risk factors for CCHFV infection, and participants’ awareness of the outbreak and infection prevention methods.
Figure 1

Provinces in Turkey where study was conducted and to which Crimean-Congo hemorrhagic fever virus is endemic (green), January–April 2009. Gray indicates other provinces and dots indicate major cities.

Provinces in Turkey where study was conducted and to which Crimean-Congo hemorrhagic fever virus is endemic (green), January–April 2009. Gray indicates other provinces and dots indicate major cities. Serum samples were tested for IgG against CCHFV at the Virology Reference Laboratory of the Refik Saydam National Public Health Agency, (Ankara, Turkey) by using a commercial ELISA kit (Vector-Best, Novosibrisk, Russia). Although the sensitivity and specificity of the kit were not specified by the manufacturer, studies that used this method have reported a sensitivity of 87%–98.3% and a specificity of 99%–100% (,). We defined subclincial cases as those in persons who were seropositive although they were not given a diagnosis or had not had severe symptoms compatible with CCHF at any time. In addition, we compared information in our database with that in the database of reported cases at the Ministry of Health, Turkey. We used the χ2 test, t test, and Mann-Whitney U test for univariate statistical comparisons, as appropriate. Multivariable logistic regression was used to assess independent risk factors for seropositivity. We used the direct standardization method to adjust age-specific seropositivity rates for our study population with the age composition of the entire outbreak region. This adjustment enabled us to calculate expected numbers of infected (seropositive) persons in the outbreak region (Technical Appendix). Clinically diagnosed cases were compared with expected numbers of infections, and an observed:expected ratio was calculated. The survey included 3,671 adults of whom 3,557 (97%) provided blood samples for serologic analysis. The mean ± SD age of the study population was 44.3 ± 16.2 years, the female:male ratio was 1.04 (51%:49%), and the most common occupation was farming (52.4%). Only 18.2% had a history of tick bite. Of 3,557 serum samples tested, 356 (10%) were positive for IgG against CCHFV. Mean ± SD age was 43.4 ± 16.2 years for seronegative persons and 52 ± 17.1 years for seropositive persons (p<0.001). Categorizing persons by age in 10-year intervals showed that seropositivity increased with age (p<0.001) (Figure 2). Univariate analysis showed that seropositive persons had less education (p<0.001), were more likely to be involved in farming, (p<0.001), and had a higher frequency of tick bites (p<0.001) than seronegative persons (Table 1). Animal husbandry as an occupation and a history of hunting were not more frequent among seropositive persons than among seronegative persons. A high proportion of seropositive persons (73.8%) and seronegative persons (71.3%), claimed that they had sufficient information about the infection and how to protect themselves (p = 0.329). Multivariable analysis results showed that an age >60 years, less schooling, farming as an occupation, and a history of tick bites were independent risk factors for seropositivity (Table 2).
Figure 2

Distribution of Crimean-Congo hemorrhagic fever virus (CCHFV)–positive persons, by age group, Turkey, January–April 2009. p<0.001, by trend test.

Table 1

Characteristics of study population tested for CCHFV, Turkey, January–April 2009*

CharacteristicSeronegative, n = 3,201Seropositive, n = 356p value
Sex
F1,634 (51.0)168 (47.2)0.167
M1,567 (49.0)188 (52.8)
Age, y, mean ± SD43.38 ± 15.8151.97 ± 17.14<0.001
18–29765 (23.9)46 (12.9)<0.001
30–39721 (22.5)55 (15.4)
40–49616 (19.2)55 (15.4)
50–59511 (16.0)57 (16.0)
60–69352 (11.0)72 (20.2)
≥70236 (7.4)71 (19.9)
Education
None607 (19.0)105 (29.7)<0.001
Elementary school1,873 (58.8)214 (60.6)
High school or university707 (22.2)34 (9.6)
Occupation
Unemployed618 (19.5)66 (18.9)<0.001
Farming1,186 (37.5)174 (49.9)
Animal husbandry553 (17.5)58 (16.6)
Other†809 (25.5)51 (14.6)
Persons living in same residence, mean ± SD5.01 ± 2.545.28 ± 2.970.177
History of hunting548 (17.6)54 (15.5)0.325
History of tick bite540 (17.0)105 (29.7)<0.001
Sufficiently informed about CCHFV2,269 (71.3)261 (73.7)0.329

*Values are no. (%) unless otherwise indicated. CCHFV, Crimean-Congo hemorrhagic fever virus.
†Retired, civil servant, factory, worker, or housewife.

Table 2

Multivariable logistic regression of risk factors for infection with CCHFV, Turkey, January–April 2009*

CharacteristicOdds ratio (95% CI)
Age, y
18–291
30–390.965 (0.630–1.480)
40–491.034 (0.669–1.599)
50–591.297 (0.832–2.023)
60–692.687 (1.723–4.191)
≥704.176 (2.638–6.611)
Education
None1
Elementary school0.977 (0.736–1.297)
High school or university0.580 (0.357–0.942)
Occupation
Unemployed and other†1
Farming1.688 (1.301–2.190)
Animal husbandry1.299 (0.922–1.832)
History of tick bite2.292 (1.768–2.971)

*CCHFV, Crimean-Congo hemorrhagic fever virus.
†Retired, civil servant, factory worker, or housewife.

Distribution of Crimean-Congo hemorrhagic fever virus (CCHFV)–positive persons, by age group, Turkey, January–April 2009. p<0.001, by trend test. *Values are no. (%) unless otherwise indicated. CCHFV, Crimean-Congo hemorrhagic fever virus.
†Retired, civil servant, factory, worker, or housewife. *CCHFV, Crimean-Congo hemorrhagic fever virus.
†Retired, civil servant, factory worker, or housewife. None of the study population had been given a diagnosis of CCHF or had been hospitalized for an acute febrile illness or severe bleeding compatible with CCHF. During 2002–2009, a total of 1,806 adults were given a diagnosis of CCHF in the outbreak region where we conducted our study (Ministry of Health, Turkey). Direct standardization of age-specific seroprevalence rates for the study population with ages of persons in the entire region showed that 15,156 infections would be expected during 2002–2008 (observed:expected ratio 0.12; 95% CI 0.114–0.125). This finding shows that only 12% of the infections were diagnosed and 88% were subclinical.

Conclusions

We found that the seroprevalence of CCHF in the study region was 10%. Hoogstraal et al. reported that the expected seroprevalence of CCHF was ≈10% during epidemics (). In a small survey in Turkey, IgG against CCHFV was detected in 12.8% of the population in high-risk areas (). Our study showed that the distribution of seropositivity increased with age (Figure 2). This finding was unexpected and showed that CCHF was present in the region long before it was recognized. However, we could not assess whether incidence or severity were amplified in recent years, which led to its detection in 2002. Seroprevalence surveys with representative samples at regular intervals may be the only way for determining if incidence of infection has increased. Another useful result from this study was the ability to predict that ≈90% of CCHFV infections were subclinical (Technical Appendix). This finding has clinical and epidemiologic implications. First, it shows that the spectrum of severity is highly skewed toward milder disease, although CCHF is believed to be a severe infection similar to other hemorrhagic fevers such as those caused by Ebola or Marburg viruses. Epidemiologically, information about subclinical cases is necessary for estimating the level of herd immunity in the population and predicting the characteristics of the outbreak. Finally, we do not know precisely why CCHF develops into a serious or fatal disease in some patients but is only a mild or asymptomatic in others (). Some studies have shown that factors such as immune response of the host, viral load, or lack of some receptors may affect the clinical form of infection (,). Some authors have suggested that geographic variation in pathogenicity of the virus () may also be a factor in severity, although the supporting data are lacking (). Therefore, timely detection and comparison of different clinical groups will be helpful in understanding the pathogenicity of the virus or host responses and developing effective treatments for infection.

Technical Appendix

Age group–specific seroprevalence rates for infection with CCHFV in the study population, Turkey, January–April 2009.
  15 in total

1.  Early serodiagnosis of acute human Crimean-Congo hemorrhagic fever virus infections by novel capture assays.

Authors:  Petra Emmerich; Tatjana Avsic-Zupanc; Sadegh Chinikar; Ana Saksida; Corinna Thomé-Bolduan; Angela Parczany-Hartmann; Arash Ghalyanchi Langroudi; Maryam Moradi; Salih Ahmeti; Stephan Günther; Jonas Schmidt-Chanasit
Journal:  J Clin Virol       Date:  2010-06-11       Impact factor: 3.168

2.  Crimean-Congo hemorrhagic fever in Southeast of Iran.

Authors:  Roya Alavi-Naini; Ali Moghtaderi; Hamid-Reza Koohpayeh; Batool Sharifi-Mood; Mohammad Naderi; Malyhe Metanat; Morteza Izadi
Journal:  J Infect       Date:  2005-09-21       Impact factor: 6.072

3.  Crimean-Congo hemorrhagic fever in Eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy.

Authors:  Zulal Ozkurt; Ilhami Kiki; Serpil Erol; Fuat Erdem; Neziha Yilmaz; Mehmet Parlak; Mehmet Gundogdu; Mehmet A Tasyaran
Journal:  J Infect       Date:  2005-06-13       Impact factor: 6.072

4.  Molecular epidemiology of African and Asian Crimean-Congo haemorrhagic fever isolates.

Authors:  F J Burt; R Swanepoel
Journal:  Epidemiol Infect       Date:  2005-08       Impact factor: 2.451

5.  Viral load as a predictor of outcome in Crimean-Congo hemorrhagic fever.

Authors:  Mustafa Aydin Cevik; Ayşe Erbay; Hürrem Bodur; Selim Sirri Eren; Esragül Akinci; Kenan Sener; Pinar Ongürü; Ayhan Kubar
Journal:  Clin Infect Dis       Date:  2007-08-23       Impact factor: 9.079

6.  Crimean-Congo haemorrhagic fever outbreak in Middle Anatolia: a multicentre study of clinical features and outcome measures.

Authors:  Mehmet Bakir; Mehmet Ugurlu; Basak Dokuzoguz; Hurrem Bodur; Mehmet A Tasyaran; Haluk Vahaboglu
Journal:  J Med Microbiol       Date:  2005-04       Impact factor: 2.472

7.  Recombinant nucleoprotein-based enzyme-linked immunosorbent assay for detection of immunoglobulin G antibodies to Crimean-Congo hemorrhagic fever virus.

Authors:  Masayuki Saijo; Tang Qing; Masahiro Niikura; Akihiko Maeda; Tetsuro Ikegami; Christophe Prehaud; Ichiro Kurane; Shigeru Morikawa
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

8.  Crimean-Congo hemorrhagic fever.

Authors:  Regina Vorou; Ioannis N Pierroutsakos; Helen C Maltezou
Journal:  Curr Opin Infect Dis       Date:  2007-10       Impact factor: 4.915

9.  Clinical and laboratory features of Crimean-Congo hemorrhagic fever: predictors of fatality.

Authors:  Mustafa A Cevik; Ayse Erbay; Hürrem Bodur; Evrim Gülderen; Aliye Baştuğ; Ayhan Kubar; Esragül Akinci
Journal:  Int J Infect Dis       Date:  2007-12-11       Impact factor: 3.623

10.  Crimean-Congo hemorrhagic fever: case series from a medical center in Golestan province, Northeast of Iran (2004).

Authors:  Ali Jabbari; Sima Besharat; Abdollah Abbasi; Abdolvahhab Moradi; Khodaberdi Kalavi
Journal:  Indian J Med Sci       Date:  2006-08
View more
  30 in total

1.  Evaluation of cases with a preliminary diagnosis of Crimean- Congo hemorrhagic fever and comparison of characteristics in patients admitted to a secondary care hospital in Kastamonu, Turkey.

Authors:  Hüseyin Can Hekimoğlu; Neşe Ateş Demirci
Journal:  Afr Health Sci       Date:  2014-12       Impact factor: 0.927

2.  Crimean-Congo Hemorrhagic Fever Mouse Model Recapitulating Human Convalescence.

Authors:  David W Hawman; Kimberly Meade-White; Elaine Haddock; Rumi Habib; Dana Scott; Tina Thomas; Rebecca Rosenke; Heinz Feldmann
Journal:  J Virol       Date:  2019-08-28       Impact factor: 5.103

3.  Critical Assessment of Metagenome Interpretation: the second round of challenges.

Authors:  Fernando Meyer; Adrian Fritz; Zhi-Luo Deng; David Koslicki; Till Robin Lesker; Alexey Gurevich; Gary Robertson; Mohammed Alser; Dmitry Antipov; Francesco Beghini; Denis Bertrand; Jaqueline J Brito; C Titus Brown; Jan Buchmann; Aydin Buluç; Bo Chen; Rayan Chikhi; Philip T L C Clausen; Alexandru Cristian; Piotr Wojciech Dabrowski; Aaron E Darling; Rob Egan; Eleazar Eskin; Evangelos Georganas; Eugene Goltsman; Melissa A Gray; Lars Hestbjerg Hansen; Steven Hofmeyr; Pingqin Huang; Luiz Irber; Huijue Jia; Tue Sparholt Jørgensen; Silas D Kieser; Terje Klemetsen; Axel Kola; Mikhail Kolmogorov; Anton Korobeynikov; Jason Kwan; Nathan LaPierre; Claire Lemaitre; Chenhao Li; Antoine Limasset; Fabio Malcher-Miranda; Serghei Mangul; Vanessa R Marcelino; Camille Marchet; Pierre Marijon; Dmitry Meleshko; Daniel R Mende; Alessio Milanese; Niranjan Nagarajan; Jakob Nissen; Sergey Nurk; Leonid Oliker; Lucas Paoli; Pierre Peterlongo; Vitor C Piro; Jacob S Porter; Simon Rasmussen; Evan R Rees; Knut Reinert; Bernhard Renard; Espen Mikal Robertsen; Gail L Rosen; Hans-Joachim Ruscheweyh; Varuni Sarwal; Nicola Segata; Enrico Seiler; Lizhen Shi; Fengzhu Sun; Shinichi Sunagawa; Søren Johannes Sørensen; Ashleigh Thomas; Chengxuan Tong; Mirko Trajkovski; Julien Tremblay; Gherman Uritskiy; Riccardo Vicedomini; Zhengyang Wang; Ziye Wang; Zhong Wang; Andrew Warren; Nils Peder Willassen; Katherine Yelick; Ronghui You; Georg Zeller; Zhengqiao Zhao; Shanfeng Zhu; Jie Zhu; Ruben Garrido-Oter; Petra Gastmeier; Stephane Hacquard; Susanne Häußler; Ariane Khaledi; Friederike Maechler; Fantin Mesny; Simona Radutoiu; Paul Schulze-Lefert; Nathiana Smit; Till Strowig; Andreas Bremges; Alexander Sczyrba; Alice Carolyn McHardy
Journal:  Nat Methods       Date:  2022-04-08       Impact factor: 28.547

Review 4.  A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health.

Authors:  Roberto Biselli; Roberto Nisini; Florigio Lista; Alberto Autore; Marco Lastilla; Giuseppe De Lorenzo; Mario Stefano Peragallo; Tommaso Stroffolini; Raffaele D'Amelio
Journal:  Biomedicines       Date:  2022-08-22

Review 5.  Crimean-Congo hemorrhagic fever: an overview.

Authors:  Serkan Oncü
Journal:  Virol Sin       Date:  2013-07-22       Impact factor: 4.327

6.  Investigation of Crimean-Congo hemorrhagic fever virus transmission from patients to relatives: a prospective contact tracing study.

Authors:  Mustafa Gokhan Gozel; Mehmet Bakir; Atifet Yasemin Oztop; Aynur Engin; Ilyas Dokmetas; Nazif Elaldi
Journal:  Am J Trop Med Hyg       Date:  2013-10-28       Impact factor: 2.345

Review 7.  Emerging Tick-Borne Diseases.

Authors:  Susan Madison-Antenucci; Laura D Kramer; Linda L Gebhardt; Elizabeth Kauffman
Journal:  Clin Microbiol Rev       Date:  2020-01-02       Impact factor: 26.132

8.  Health care response to CCHF in US soldier and nosocomial transmission to health care providers, Germany, 2009.

Authors:  Nicholas G Conger; Kristopher M Paolino; Erik C Osborn; Janice M Rusnak; Stephan Günther; Jane Pool; Pierre E Rollin; Patrick F Allan; Jonas Schmidt-Chanasit; Toni Rieger; Mark G Kortepeter
Journal:  Emerg Infect Dis       Date:  2015-01       Impact factor: 6.883

9.  The seroprevalance of Crimean-Congo haemorrhagic fever in people living in the same environment with Crimean-Congo haemorrhagic fever patients in an endemic region in Turkey.

Authors:  I Koksal; G Yilmaz; F Aksoy; S Erensoy; H Aydin
Journal:  Epidemiol Infect       Date:  2013-05-21       Impact factor: 4.434

10.  Immunization of knock-out α/β interferon receptor mice against high lethal dose of Crimean-Congo hemorrhagic fever virus with a cell culture based vaccine.

Authors:  Nurettin Canakoglu; Engin Berber; Sukru Tonbak; Mustafa Ertek; Ibrahim Sozdutmaz; Munir Aktas; Ahmet Kalkan; Aykut Ozdarendeli
Journal:  PLoS Negl Trop Dis       Date:  2015-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.